Ipsen SA (IPN)

102.60
-4.50(-4.20%)
  • Volume:
    124,961
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    99.60 - 105.10

IPN Overview

Prev. Close
107.1
Day's Range
99.6-105.1
Revenue
2.29B
Open
103.7
52 wk Range
77-121
EPS
8.95
Volume
124,961
Market Cap
8.45B
Dividend (Yield)
1.20
(1.17%)
Average Vol. (3m)
82,988
P/E Ratio
11.64
Beta
0.81
1-Year Change
18.03%
Shares Outstanding
82,407,385
Next Earnings Date
Feb 09, 2023
What is your sentiment on Ipsen?
or
Market is currently closed. Voting is open during market hours.

Ipsen SA Analysis

Ipsen SA Company Profile

Ipsen SA Company Profile

Employees
5744
Market
France
  • Type:Equity
  • Market:France
  • ISIN:FR0010259150

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy